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Abstract
To investigate the association between cannabis smoking and lung cancer risk, data on 2,159 lung 
cancer cases and 2,985 controls were pooled from 6 case-control studies in the US, Canada, UK, 
and New Zealand within the International Lung Cancer Consortium. Study-specific associations 
between cannabis smoking and lung cancer were estimated using unconditional logistic regression 
adjusting for sociodemographic factors, tobacco smoking status and pack-years; odds-ratio 
estimates were pooled using random effects models. Subgroup analyses were done for sex, 
histology and tobacco smoking status. The shapes of dose-response associations were examined 
using restricted cubic spline regression. The overall pooled OR for habitual versus nonhabitual or 
never users was 0.96 (95% CI: 0.66–1.38). Compared to nonhabitual or never users, the summary 
OR was 0.88 (95%CI: 0.63–1.24) for individuals who smoked 1 or more joint-equivalents of 
cannabis per day and 0.94 (95%CI: 0.67–1.32) for those consumed at least 10 joint-years. For 
adenocarcinoma cases the ORs were 1.73 (95%CI: 0.75–4.00) and 1.74 (95%CI: 0.85–3.55), 
respectively. However, no association was found for the squamous cell carcinoma based on small 
numbers. Weak associations between cannabis smoking and lung cancer were observed in never 
tobacco smokers. Spline modeling indicated a weak positive monotonic association between 
cumulative cannabis use and lung cancer, but precision was low at high exposure levels. Results 
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from our pooled analyses provide little evidence for an increased risk of lung cancer among 
habitual or long-term cannabis smokers, although the possibility of potential adverse effect for 
heavy consumption cannot be excluded.
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Background
Cannabis is the world's most widely used illicit substance with between 119 million and 224 
million users worldwide. In 2010, the proportion reporting use of cannabis in the past year 
was 2.6– 5% for persons aged 15–64, with highest frequency observed in Oceania (9.1–
14.6%) and North America (10.8%).1 In the US, frequency of cannabis use has continued to 
rise2 especially among teenagers, a trend that has been attributed to falling perceived risk.1 
The three main forms of cannabis products are the flower or herb (marijuana), resin 
(hashish), and oil (hashish oil), and their relative levels of consumption vary globally by 
region. Resin dominates the markets in the Near- and Middle-East as well as Southwest 
Asia; resin and herb markets are comparable in size in Northern Africa and Europe; whereas 
cannabis herb dominates the rest of the world including North America.1
Lung cancer remains the leading cause of cancer death worldwide, and use of tobacco is 
recognized as the main risk factor.3–5 Cannabis is mainly consumed by smoking, and 
cannabis smoke shares carcinogens with tobacco smoke including polycyclic aromatic 
hydrocarbons such as benzo[α]pyrene and phenols.5–7 Different smoking techniques result 
in 3-fold higher levels of tar and 5-fold higher levels of carbon monoxide being retained in 
the lungs during cannabis smoking as compared to tobacco smoking.8 Therefore, cannabis 
has been hypothesized to be a risk factor for tobacco-related cancers including that of the 
lung. Previous studies have demonstrated precancerous histological9,10 and molecular 
abnormalities11 in the respiratory tracts of cannabis smokers. In addition, in vitro12 and in 
vivo animal studies have demonstrated the carcinogenic effects of cannabis or its 
constituents.13,14 However, epidemiological studies investigating the association between 
cannabis smoking and lung cancer have been limited, sample sizes generally small, and 
results conflicting.15–22
Established in 2004, the International Lung Cancer Consortium (ILCCO) brings together an 
international group of lung cancer researchers with the aim of sharing comparable data from 
ongoing and recently completed lung cancer case-control and cohort studies from different 
geographical areas and ethnicities. One of the key goals of the ILCCO is to explore potential 
lung cancer risk factors that are difficult to evaluate in individual studies. To address the 
limitations of prior studies and to further explore the link between cannabis smoking and 
lung cancer development, particularly nonlinear dose-response relations and associations 
among never tobacco smokers and other subgroups, we conducted a pooled analysis based 
on individual-level data from participating ILCCO studies.
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Methods
Data collection
Details of the International Lung Cancer Consortium and the requirements for inclusion of 
studies have been previously published23 and are available on the Consortium portal (http://
ilcco.iarc.fr). Six ILCCO studies have collected information on cannabis smoking and 
contributed primary data in this pooled analysis investigating the association between 
cannabis smoking and lung cancer risk. Two studies had previously reported effect estimates 
for cannabis smoking,15,16 whereas the remaining studies represented unpublished data for 
the association of interest. All studies considered primary, incident and histologically 
confirmed lung cancer cases. Written informed consent was obtained from all study 
subjects, and individual study protocols were approved by site-specific institutional ethic 
review boards. Deidentified data received from individual studies were checked for missing 
values, inadmissible values, aberrant distributions and inconsistencies. Subjects with 
unknown age, sex, race or habitual versus nonhabitual cannabis smoking status were 
excluded. An additional 6 subjects, whose joints smoked per day exceeded 40 or lifetime 
duration of cannabis smoking exceeded 70 years, were deemed outliers or potential data 
errors based on the overall distribution. The final pooled analysis sample consisted of 2,159 
cases and 2,985 controls.
Statistical methods
Data on individual-level cannabis smoking consumption were based on self-reported 
responses to questions on study-specific questionnaires. We defined lifetime habitual use of 
cannabis as having a cumulative consumption of at least 1 joint-year (i.e., equivalent to 
smoking 1 joint/day for 1 year). Joint-equivalent was defined as the average cannabis plant 
matter contained in a typical joint or 0.75 g/joint when the unit of reporting was weight or 
the mode of consumption was other than joint.24 We also harmonized variables pertaining to 
total duration (years) and intensity of cannabis smoking (average joint-equivalents smoked 
per day during periods of cannabis use); and cumulative cannabis smoking in joint-years, 
calculated by multiplying the first two variables for each subject.
Variables for demographic characteristics and well-established lung cancer risk factors were 
harmonized across studies. Self-reported tobacco smoking status at interview was defined as 
never smokers (<100 cigarettes over lifetime or according to study-specific cut-offs), former 
smokers (stopped smoking at least 2 years prior to interview), and current smokers (smoked 
within the past 2 years). The latter two categories make up the ever group in never versus 
ever definition for tobacco-smoking status. For current and former tobacco smokers, 
cumulative tobacco smoking expressed in pack-years was calculated as the product of 
smoking intensity (pack-equivalent per day) and the sum of smoking periods over the 
person's lifetime. When education level (<3%) or tobacco pack-years were missing (<5%), 
values were imputed using the median of the study-, age-, and sex-specific control 
population for education, and the median of the study-, age-, sex-, and smoking status-
specific control population for pack-years.
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The overall association between cannabis smoking (habitual vs. nonhabitual or never users, 
joint-equivalents per day, duration, total joint-years, and age of cannabis smoking onset) and 
the risk of all lung cancer, adenocarcinoma, and squamous cell carcinoma (as sample size 
permitted) was assessed by odds ratios (OR) and 95% confidence intervals (CI) obtained 
from unconditional logistic regression in each study, adjusting for age, sex, race, highest 
education, status of tobacco smoking (never vs. ever) and pack-years of tobacco smoking 
(continuous). Because of collinearity and small sample sizes, models for continuous 
exposure variables for the Moffitt Cancer Study and Memorial Sloan-Kettering Cancer 
Center Study were restricted to the adjustment of the essential covariates: age, sex and 
tobacco smoking pack-years. Tobacco smoking status (never vs. ever) was additionally 
adjusted where possible. Study-specific effect estimates were pooled across studies using 
random effect models to account for heterogeneity between study populations. Interstudy 
heterogeneity was evaluated based on the Q-statistic and I2 statistic.25 When the p-value for 
heterogeneity across studies was less than 0.05, influence analysis was performed to 
evaluate the source of heterogeneity from single studies using Galbraith plots,26 and 
excluding the study contributing most to the Q-statistic. Stratified analyses were done to 
examine the associations between cannabis smoking and all lung cancer for males and 
females separately. As an alternative method to control for confounding by tobacco 
smoking, as sample sizes allowed, we also conducted analyses restricted to those who never 
smoked tobacco (370 cases and 1,358 controls) by pooling individual level data of never 
smokers from all available studies; the associations between cannabis and lung cancer risk 
was then assessed with unconditional logistic regression adjusting for age, sex, highest 
education, race and study.
The shapes of nonlinear dose-response associations between the continuous exposure 
variables (joint equivalent per day, duration and overall joint-years) and lung cancer were 
examined using restricted cubic spline regression with 5 knots, adjusting for age, sex, race, 
highest education, tobacco smoking status (never vs. ever) and pack-years, as well as 
study.27 Study-specific multivariable unconditional logistic regression and pooled analysis 
for never smokers were conducted in SAS, while the pooled effect estimates and restricted 
cubic spline analyses were done in R package.
Results
The characteristics of the 6 participating case-control studies in ILCCO are summarized in 
Table 1. Except for one family-based study, the remaining studies include 2 that used 
population-based controls and 3 that used hospital or clinical-based controls that were 
frequency matched to cases on at least age and sex. Four studies were conducted in North 
America (3 in the US and 1 in Canada), while the remaining 2 studies were set in the UK 
and New Zealand. In all studies, cannabis consumption was assessed using self-reported 
levels on standard questionnaires or surveys. In total, 2,159 lung cancer cases and 2,985 
controls were included in the analysis. The frequency distributions of demographic, 
histology and lung cancer risk factors for both the total population and never tobacco 
smokers are summarized in Table 2. Although the average age of controls was slightly 
younger than cases (median age was 53.0 ± 10.4 for controls vs. 57.3 ± 10.5 for cases), 
subjects were comparable with respect to sex and race distributions, with over 75% of 
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subjects being White/Caucasian. As expected, controls were less likely than cases to have 
ever smoked tobacco. Squamous cell carcinoma (n = 394), adenocarcinoma (n = 913) and 
small cell lung cancer (n = 273) histologic subtypes make up over 70% of all cases in the 
study sample (Table 2).
The frequency distribution of cannabis smoking variables for the overall population and 
never tobacco smokers as well as the pooled risk estimates are summarized in Table 3. The 
estimated ORs of all lung cancer associated with habitual cannabis smokers as compared to 
nonhabitual or never cannabis smokers in the participating studies ranged from 0.57 (95% 
CI: 0.30–1.07) in the Mount Sinai Hospital-Princess Margaret Hospital (MSH-PMH) study 
to 2.17 (95% CI: 1.04–4.52) in the New Zealand study (Fig. 1). The overall summary OR 
was 0.96 (95% CI: 0.66–1.38, p for heterogeneity: 0.17) (Table 3), and there was no 
detectable heterogeneity in the effect estimates for studies that used population-based 
controls vs. hospital or clinic-based controls (p = 0.24).
Compared to nonhabitual or never users, the pooled OR was 0.88 (95% CI: 0.63–1.24) for 
individuals who smoked 1 or more joint-equivalents per day and 1.03 (95%CI: 0.54–1.98) 
for individuals who smoked cannabis for 20 years or more (Table 3) for all lung cancer 
cases. Also, compared to nonhabitual or never users, the OR for those who started smoking 
cannabis before 19 years of age was 0.86 (95% CI: 0.62–1.19).
In general, sex-specific analyses yielded results comparable to those obtained for all lung 
cancer cases and were therefore not presented in detail. For example, compared to 
nonhabitual or never cannabis users, the ORs for habitual users are 0.84 (95%CI: 0.60, 1.18) 
for men and 0.94 (95%CI: 0.62, 1.40) for women. The OR for those who smoked cannabis 
more than 20 years was 0.80 (95%CI: 0.55, 1.16) for men and 1.05 (95%CI: 0.48, 2.82) for 
women.
No overall association between cannabis smoking and all lung cancer was detected among 
never tobacco smokers; habitual versus nonhabitual or never user OR was 1.03 (95% CI: 
0.51–2.08). Effect estimates for the other categorical cannabis variables were too imprecise 
to be informative due to the small numbers of exposed cases. For example, the OR was 1.64 
(95%CI: 0.45–6.00) for those who smoked 20 years or more versus those nonhabitual or 
never smokers (Table 3), and it was 0.54 (95% CI: 0.12–2.55) for 10 or more joint-years of 
cannabis use versus less than 1 joint-year. The majority of the never tobacco-smoking lung-
cancer cases are female (272 out of a total of 370), and restricting the analysis to female 
nontobacco smokers yielded comparable results: Compared to nonhabitual or never users, 
the OR was 0.94 (95%CI: 0.62, 1.40) for habitual cannabis users and 1.05 (95%CI: 0.48, 
2.28) for those who smoked for 20 years or more.
The results for the largest histologic subgroup, adenocarcinoma, are presented in Table 4. 
There was a suggestive association between high intensity and cumulative cannabis smoking 
on adenocarcinoma lung cancer. Compared to non-habitual or never users, the OR for users 
who smoked one or more joint-equivalents per day was 1.73 (95% CI: 0.75–4.00), and OR 
for those with cumulative exposure of 10 joint-years or more was 1.74 (95% CI: 0.85–3.55) 
(Table 4). Nonetheless, we observed little association with the duration of cannabis 
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smoking; the OR was 1.08 (95% CI: 0.60–1.96) for those who smoked for 20 years or more. 
Only 4 of the studies have sufficient data for squamous cell carcinoma. Compared to non-
habitual or never users, the estimated OR for squamous cell carcinoma was 1.55 (95%CI: 
0.35–6.87) for those who smoked one or more joint-equivalents per day and 1.58 (95%CI: 
0.48–5.20) for smokers of more than 20 years. The estimated OR for the association 
between cumulative exposure of 10 or more joint-years (vs. less than 1 joint-year) and lung 
cancer was 2.35 (95%CI: 0.48–11.46). The confidence intervals were very wide due to 
smaller sample sizes of squamous cell carcinoma.
Use of restricted cubic splines to examine the dose-response associations between cannabis 
use and lung-cancer incidence did not exhibit monotonic associations for average joints per 
day or duration of use (Figs. 2a and 2b). There was, however, a positive monotonic 
association between joint-years of cannabis use and lung cancer (Fig. 2c); but the 95% 
confidence bands were wide, especially for higher exposure levels.
Discussion
In this study, we harmonized and pooled individual-level data from 6 ILCCO studies and 
examined the association with lung cancer for cannabis smoking status, age of start, 
intensity, duration and cumulative exposure in all subjects and subgroups by sex and 
histologic subtype where sample size allowed, and also separately for never tobacco 
smokers. In our pooled results, we found little or no association between the intensity, 
duration, cumulative consumption or age of start of cannabis smoke and the risk of lung 
cancer in all subjects or never smokers, and suggestive association for adenocarcinoma. The 
evidence for the association with other histological subtypes is limited by the small sample 
size. In the spline analyses, there was a weak increasing trend over long-term and high levels 
of cumulative cannabis smoking exposure. The confidence intervals were wide due to the 
limited number of observations at the high exposure levels, but the results are more 
compatible with an association with lung cancer at high levels of cannabis exposure than 
with no association. In addition, misclassification of cannabis use no doubt occurred and 
may have flattened or distorted the dose-response relation.
The consumption of psychoactive substances such as cannabis and tobacco are often highly 
correlated. Therefore, given the established link between tobacco smoking and lung cancer, 
confounding by tobacco smoking is one of the major concerns in studies attempting to 
elucidate the association between cannabis smoking and lung cancer. In this study, we found 
habitual cannabis users were much more likely than nonhabitual or never users to be tobacco 
smokers (86.3% vs. 64.0%, p < 0.001). Similarly, tobacco smokers were more likely than 
never smokers to use cannabis habitually (13.8% vs. 4.3%, p < 0.001). Comparing cannabis 
users who also smoked tobacco versus those who used cannabis alone, users of both 
products were more likely to be males and with low to medium education levels (data not 
shown). We expect that the association of cannabis and tobacco smoking would lead to 
upward confounding of the cannabis association with lung cancer, and that misclassification 
of cigarette consumption would be a source of overestimating the strength of the cannabis-
lung cancer association in our data.
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One of the key advantages of this pooled analysis was the examination of the association 
between cannabis smoking and lung cancer among never tobacco smokers, and these 
findings were consistent with the results in the total sample. The use of random-effect 
models in the pooled analysis reduced the likelihood of larger studies overly influencing the 
effect estimates. Since all studies in this pooled analysis were case-control studies, and 
medical cannabis may have been used by some to alleviate pain caused by cancer or pre-
cancer symptoms, there is possible reverse causality. However, our results did not change 
after excluding any cannabis exposures within 2 years prior to the date of diagnosis or 
interview (data not shown), arguing against reverse causality.
Our pooled results are consistent with a previous systematic review of observational studies 
on the association between marijuana smoking and lung cancer, which also found no 
association after adjusting for tobacco use.31 However, in a pooled analysis of three studies 
conducted in Maghreb restricted to men, the OR was 2.3 (95% CI: 1.5–3.6) for ever 
cannabis smoking comparing lung cancer cases to hospital-based controls, after adjusting for 
tobacco smoking and other potential confounders.17 The investigators of that study also 
observed an increased risk of lung cancer with increasing joint-years.17 But as the authors 
pointed out, the practice of mixing of tobacco with cannabis in the region would lead to 
upward residual confounding by tobacco smoking. In a recently published 40-year cohort 
study among Swedish military conscripts, a positive association was observed between 
heavy cannabis smoking (defined as more than 50 times in total) at baseline and lung–cancer 
incidence32; however, there are important concerns regarding potential reporting bias, 
association of tobacco and cannabis smoking behaviors (especially changes in such 
behaviors since cohort entry), and residual confounding by tobacco smoking, all of which 
may have affected the validity of the findings.
The dose of cannabis product consumption differs by source of plant material, its 
processing, and by smoking techniques including the depth of inhalation and breath-holding, 
number and frequency of puffs, as well as how much of the joint is smoked. In addition, the 
amount of combustion byproduct varies by the mode of consumption. Because of the varied 
levels of information collected by individual studies, we were unable to examine these 
effects in this pooled analysis. We observed interstudy heterogeneity, and it is possible that 
this heterogeneity is due to differing characteristics of the individual studies such as the 
prevailing cannabis product being consumed in the study region, and differential recall bias 
between in-person versus self-administered questionnaire formats. Because of the limited 
number of studies, we were unable to fully explore such sources of heterogeneity using 
meta-regression. However, we detected no difference in the pooled ORs between 
population-based case-control studies and hospital or clinic-based studies. The study that 
contributed most of the observed heterogeneity is the New Zealand study, which is also the 
study that reported the strongest association between cannabis smoking and lung cancer risk. 
The exclusion of this study resulted in the ORs closer to null, with a much reduced 
heterogeneity.
Cannabis use is under international control and its legal status varies, so reporting bias is of 
concern. The reported prevalence among controls in the study populations is comparable to 
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nation or region-specific survey results.33–35 Greater under-reporting by cases as compared 
to controls might explain the lack of observed association.
Cannabis is usually smoked without a filter, and smoking dynamics studies among habitual 
marijuana users show that the overall burden of particulates delivered to the respiratory tract 
is about 4 times greater when smoking marijuana than when smoking the same amount of 
tobacco.8 When compared to tobacco smoke, cannabis tends to burn at a higher temperature 
(which may accelerate biochemical processes) and cannabis smoke is typically inhaled 
deeper and held longer.36 On the other hand, the quantity of cannabis smoked by chronic 
users is typically far less than the quantity of tobacco smoked by chronic cigarette smokers.
Other potential health effects of cannabis smoking that have been reported include those on 
the cardiovascular system,37–39 the development of drug dependence, and subtle cognitive 
impairment. Inconclusive findings of cannabis use being associated with mild changes in 
pulmonary function40–44 have also been reported, as have its benefits on fasting glucose.45 
The changing social and legal status of cannabis in the United States may however 
complicate the picture by altering patterns of consumption methods. Specifically, respiratory 
risks may differ with the use of water pipes and vaporizers or with consuming oral 
preparations.
Given the popularity of cannabis use, particularly among younger populations, it is 
important to have reliable estimates of health consequences. Our study highlights the need 
for comprehensive and standardized measures of quantity and methods of cannabis 
consumption, along with accurate measures of tobacco consumption to insure confounding 
control. To address the small sample size with very high exposures and histological subtypes 
(other than adenocarcinoma), future epidemiologic studies need to include sufficient 
numbers of heavy users and specific histological subtypes of interests. Prospective follow-
up studies of the health effects are also needed.
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What's new?
Due to the potential adverse effect of cannabis smoking and its popularity, an 
investigation of its association with lung cancer risk is essential to help support 
appropriate regulations as well as health and social policy responses. The analysis 
presented here included the largest data set on cannabis and lung cancer risk to date. Its 
non-linear dose-response was examined using restricted cubic spline regression, a first in 
this line of work. Results provide little evidence for an increased risk of lung cancer 
among habitual or long-term cannabis smokers, although the possibility of potential 
adverse effect for heavy consumption cannot be excluded.
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Figure 1. 
Forest plot of the association between cannabis smoking (habitual vs. nonhabitual) and lung 
cancer risk. Pooled, pooled OR according to a random effects model (p-heterogeneity = 
0.17). Abbreviations: No.: Number; Exp.: Number exposed; CI: confidence interval. MSH-
PMH study, The Mount Sinai Hospital-Princess Margaret Hospital Study; MSKCC study, 
The Memorial Sloan-Kettering Cancer Center Study; UCLA study, The University of 
California at Los Angeles Study.
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Figure 2. 
Restricted cubic spline (5 knots) to explore nonlinear association between cannabis smoking 
and lung cancer risk in all subjects showing the fitted odds of being a case versus being a 
control under different exposure measurements: (a) Joint-equivalents per day; (b) Duration; 
(c) Joint-years. Gray area, 95% confidence interval. Each model was adjusted for age, sex, 
race, highest education, tobacco smoking status and packyears, and study.
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